help button home button Biophys. J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Originally published as Biophys J. BioFAST on June 15, 2007.
doi:10.1529/biophysj.107.106369
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
biophysj.107.106369v1
93/8/2813    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonomi, M.
Right arrow Articles by Parrinello, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonomi, M.
Right arrow Articles by Parrinello, M.
Biophysical Journal 93:2813-2821 (2007)
© 2007 The Biophysical Society

Insight into the Folding Inhibition of the HIV-1 Protease by a Small Peptide

Massimiliano Bonomi *, Francesco L. Gervasio *, Guido Tiana {dagger}, Davide Provasi {dagger}, Ricardo A. Broglia {dagger} {ddagger} and Michele Parrinello *

* Computational Science, Department of Chemistry and Applied Biosciences, ETH Zürich, Lugano, Switzerland; {dagger} Department of Physics, University of Milan, Milan, Italy; and {ddagger} The Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark

Correspondence: Address reprint requests to Massimiliano Bonomi, Computational Science, Dept. of Chemistry and Applied Biosciences, ETH Zürich, c/o USI Campus, via Buffi 13, CH-6900 Lugano, Switzerland. E-mail: massimiliano.bonomi{at}phys.chem.ethz.ch.

It has recently been shown that the highly protected segments 24–34 (S2) and 83–93 (S8) of each of the two 99-mers of human immunodeficiency virus type 1 protease play an essential role in the folding of the monomers, giving rise to the so-called (postcritical) folding nucleus ((FN) minimum condensation unit ensuring folding) when they dock. This scenario received further support from model calculations that demonstrated that the peptide p-S8, displaying an amino acid sequence identical to the corresponding (83–93) segment of the monomer, can be used to interfere with the formation of the FN and eventually to inhibit folding by docking the fragment 24–34. Experiments in vitro and in cells infected with ex vivo wild-type and multiresistant HIV isolates confirm that the inhibition power of p-S8 is robust. On the other hand, there is no direct evidence demonstrating the validity of the proposed mechanism of inhibition associated with p-S8. To shed light on this question and to provide the basis for the design of a molecule mimetic to p-S8, to be used as lead of an eventual drug against AIDS, we study, in this paper, with the help of all-atom simulations in explicit solvent and the novel method of metadynamics combined with parallel tempering: a), the free energy and the equilibrium structure of each of the peptides p-S2 and p-S8; b), the details of the docking mechanism of the two peptides and the free energy associated with this process. Whereas p-S8 is found to be well structured, p-S2 is rather flexible, wrapping itself around p-S8 to give rise to the FN, which is stabilized by three particular hydrogen bonds.




This article has been cited by other articles:


Home page
Biophys. JHome page
G. Verkhivker, G. Tiana, C. Camilloni, D. Provasi, and R. A. Broglia
Atomistic Simulations of the HIV-1 Protease Folding Inhibition
Biophys. J., July 15, 2008; 95(2): 550 - 562.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Biophysical Society.